Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma
- Focus Therapeutic Use
- 15 Dec 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2020.
- 12 Jul 2016 Planned End Date changed from 1 Sep 2018 to 1 Sep 2020.
- 12 Jul 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2018.